Hello,
Welcome to a special Black Friday edition of
- A rushed Teladoc and Livongo merger led to a wave of senior exits;
- Getting patents could make or break psychedelic companies;
- One of Moderna's top scientists on why he thinks gene editing is the future of the company.
Comments, tips? Email me at lrosenbaum@insider.com or tweet @leah_rosenbaum. Let's get to it...
Sign up today and become an Insider for our lowest annual subscription rate ever — just $38 for full access to everything we offer.
Teladoc acquired Livongo to recreate healthcare. A rushed union, a wave of senior exits, and sky-high expectations are testing the $14 billion bet.
- It's been one year since
Teladoc 's megamerger with the chronic-care companyLivongo . - The goal is to build one app that covers primary care, chronic care, and other services.
- Teladoc has faced internal and external pressure, and more than 110 Livongo employees have left.
The future of the psychedelics industry hinges on patents. Whoever wins could make billions.
- The nascent psychedelics industry is headed toward a reckoning.
- Experts say a slew of patent disclosures could determine the winners and losers of the space.
- That may also set off a wave of M&A as companies vie to win market share.
The scientist who helped Moderna become a vaccine powerhouse tells us why he thinks gene editing is the future for the $91 billion biotech
- Eric Huang, who persuaded
Moderna to make vaccines, is now steering the biotech intogene editing . - Huang is the chief scientific officer of Moderna Genomics, a new unit in the $91 billion company.
- Huang intends to strike deals with smaller biotechs while building up Moderna's internal research.
In case you missed it:
- How Amy Abernethy is rejiggering one of Verily's biggest bets to change clinical research and propel the Google spin-off into the future
- See the 16-slide presentation a former Uber exec used to raise $25 million to tackle the growing in-home care market
- The health-insurance giant UnitedHealth is sending more members to in-house doctors in a bid to lower costs and increase profits
- Cathie Wood's Ark has scooped up shares of Ginkgo and Zymergen as their stocks fell. Here's why she's betting synthetic biology will be the next wave of drug development.
-Leah